Purple BiotechPurple Biotech
  • Home
  • About us
    • Our History
    • Mission
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • CM24
    • NT219
    • IM1240
    • Publications
  • Investors
    • Overview
    • News & Events
    • Press Releases
    • SEC Filings
    • Shareholders’ Meetings
    • Email Alerts
    • Corporate Governance
  • Contact us
menu
  • Home
  • About us
  • Pipeline
  • Investors
  • Contact Us
To Top

Author: yarone

Categories

  • News and Events
    • Events
    • News
  • Publications
    • CM-24
    • more about CM-24
    • more about NT-219
    • NT-219

Posts

  • Purple Biotech will present a poster titled: ‘Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced Pancreatic Cancer – Survival, Potential Biomarker and Effect on Neutrophil Extracellular Traps (NETs)’ at the AACR Special Conference: Pancreatic Cancer, September 27-30, 2023. Presentation date and time: September 28 at 4:40 pm, 2023
  • Drug Discovery World article on NT219 poster publication on AACR23: “New drug could help overcome tumour resistance to treatment”
  • NT219 induces tumor PD-L1 expression and potentiates anti-PD-1efficacy
  • Purple Biotech to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.
  • Purple Biotech Presents NT219 Pre-Clinical Data at the AACR 2023 Annual Meeting.
  • Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.
  • Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.
  • Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.
  • Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.
  • Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023
Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors

Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors

By yarone
in
NT-219
Publications
Jun 16, 2022

Presented at the ASCO annual meeting 2022

Read more

IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy

By yarone
in
NT-219
Publications
Oct 25, 2021

Published in Nature Cancer, October 2021

Read more
A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer

A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer

By yarone
in
CM-24
Publications
Sep 29, 2021

Presented at the ESMO annual meeting 2021

Read more
Adaptation of Colorectal Cancer Cells to the Brain Microenvironment The Role of IRS2

Adaptation of Colorectal Cancer Cells to the Brain Microenvironment The Role of IRS2

By yarone
in
NT-219
Publications
Apr 12, 2021

Presented at the AACR annual meeting 2021

Read more

View more: CM-24 references

By yarone
in
more about CM-24
Jan 01, 2021
Download PDF file
Read more

View more: NT-219 References

By yarone
in
more about NT-219
Jan 01, 2021
Download PDF file
Read more
A Phase 1 Open-label Multicenter Single Dose Escalation and Multi-dose Study of a mAb Targeting CEACAM1 in Subjects with Selected Advanced or Recurrent Malignancies

A Phase 1 Open-label Multicenter Single Dose Escalation and Multi-dose Study of a mAb Targeting CEACAM1 in Subjects with Selected Advanced or Recurrent Malignancies

By yarone
in
CM-24
Publications
May 01, 2020

Presented at the ASCO annual meeting 2020

Read more
NT219, a Novel Dual Inhibitor of STAT3 and IRS1/2, Demonstrates Anti-Tumor Activity With and Without Cetuximab in Pembrolizumab-Resistant Head and Neck Cancer PDX Models

NT219, a Novel Dual Inhibitor of STAT3 and IRS1/2, Demonstrates Anti-Tumor Activity With and Without Cetuximab in Pembrolizumab-Resistant Head and Neck Cancer PDX Models

By yarone
in
NT-219
Publications
Apr 01, 2020

Presented at the AACR annual meeting 2020

Read more
A phase I/II, Open-label, Dose Escalation Followed by Single-arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with R/M HNSCC

A phase I/II, Open-label, Dose Escalation Followed by Single-arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with R/M HNSCC

By yarone
in
NT-219
Publications
Feb 01, 2020

Presented at the 2020 multidisciplinary Head and Neck Cancers Symposium

Read more
NT219, A Novel Bi-specific Inhibitor of STAT3 and IRS1/2, Combined with Chemotherapy or MEK Inhibitor in Gemcitabine-Resistant Pancreatic Tumors, Induced Tumor Regression

NT219, A Novel Bi-specific Inhibitor of STAT3 and IRS1/2, Combined with Chemotherapy or MEK Inhibitor in Gemcitabine-Resistant Pancreatic Tumors, Induced Tumor Regression

By yarone
in
NT-219
Publications
Apr 01, 2019

Presented at the 2019 AACR Special Conference Pancreatic Cancer

Read more
1 2 Next »
Corporate Headquarters

4 Oppenheimer St.
Science Park, Rehovot
Israel 7670104
Tel : + 972-3-9333121

ir@purple-biotech.com

 

Follow Us
linkedin
Purple biotech
  • Investors
  • Pipeline
  • About us
  • Contact Us

2021 All Rights Reserved. Created BY ATEAS.BIZ

  • Home
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset